Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 34, Issue 11, 2013, Pages 1084-1089

  Ocak, Meltem ^a   Demirci, Emre ^a   Kabasakal, Levent ^a   Aygun, Aslan ^a   Tutar, Rumeysa O ^a   Araman, Ahmet ^a   Kanmaz, Bedii ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ga 68 DOTA NOC; Ga 68 DOTA TATE; octreotide; somatostatin receptor; thyroid cancer

Indexed keywords

1 4 7 10 TETRAAZACYCLODODECANE 1 4 7 10 TETRAACETIC ACID 1 NAL3 OCTREOTIDE GA 68; 1 4 7 10 TETRAAZACYCLODODECANE 1 4 7 10 TETRAACETIC ACID DEXTRO PHENYL1 TYROSINE3 OCTREOTATE GA 68; IODINE 131; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; TETRAXETAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DRUG STABILITY; DRUG UPTAKE; FEMALE; FOLLICULAR THYROID CARCINOMA; HUMAN; HURTHLE CELL CARCINOMA; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; LUNG METASTASIS; MALE; PET SCANNER; PROTEIN EXPRESSION; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84885021289     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328364eaab     Document Type: Article

References (15)

1. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17:R53-R573.
2. Srirajkanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of Ga-68 DOTATATE in patients with neuroendocrine tumors and negative or equivocal findings on In-111 DTPA octreotide scintigraphy. J Nucl Med 2010; 51:875-882.
3. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. Ga-68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518. (Pubitemid 47571404)
4. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. Ga-68 DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with In-111 DTPA octreotide (Octreoscan). Mol Imaging Biol 2011; 13: 583-593.
5. Frilling A, Sotiropoulos C, Radtke A, Malago M, Bockish A, Kuehl H, et al. The impact of Ga-68 DOTATOC positron emission tomography/computed tomography on multimodal management of patients with neuroendocrine tumors. Ann Surg 2010; 252:850-856.
6. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: Ga-68 DOTATyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50:1214-1221.
7. Ambrossini V, Campana D, Bodei L, Nanni C, Castelluci P, Allegri V, et al. Ga-68 DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010; 51:669-673.
8. Wild D, Schmitt JS, Ginj M, Macke H, Bernard BF, Krenning E, et al. DOTANOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3, and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30:1338-1347. (Pubitemid 37247950)
9. Pettino C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. Ga-68-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 51:72-79. (Pubitemid 350234154)
10. Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of Ga-68-DOTATATE and Ga-68-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39:1271-1277.
11. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of Ga-68-DOTANOC and Ga-68-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013; 54:1-9.
12. Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin subtype expression in human thyroid tumours. Horm Metab Res 2010; 42:237-240.
13. Pazaitou-Panayiotou K, Janson ET, Koletsa T, Kotoula V, Stridsberg M, Karkavelas G, Karayannopoulou G. Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones 2012; 11:290-296.
14. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of Ga-68 labelled peptides. Nucl Med Commun 2007; 28:870-875. (Pubitemid 47494113)
15. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in Ga-68-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:48-52.